PARK7 and hepatocellular carcinoma: To further confirm if FGFR1 plays a vital role in sorafenib resistance in HCC cells, we first chose HUH-7/R cell line as our model and treated HUH-7/R cells at different conditions, i.e., vehicle control, sorafenib, sorafenib plus DJ-1, and sorafenib plus DJ-1 and FGFR1 knockdown, where were then injected subcutaneously into immunodeficient mice (i.e., nude mice).